For more information, contact us at:
1.877.CRIVER.1 (1.877.274.8371)askcharlesriver@crl.com
*indicates a required field.
The information you provided will be kept confidential.
Mar 02
Representatives from leading contract research organizations (CROs) weigh in on key challenges tied to the biopharmaceutical R&D, including issues regarding bioequivalence, platform technologies, process analytics, and more. Charles River’s Nancy Gillett, PhD, corporate executive vice-president and president of Global Preclinical Services, participated in this roundtable.
Feb 13
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2011. For the quarter, net sales from continuing operations were $291.0 million, an increase of 3.3% from $281.7 million in the fourth quarter of 2010. On a segment basis, sales increased in the Research Models and Services (RMS) segment, but declined in the Preclinical Services (PCS) segment. The addition of a 53rd week at the end of 2011, which is periodically required to true up to a December 31st fiscal year end, contributed approximately 4.5% to reported fourth-quarter sales. At a 0.2% benefit, the impact of foreign currency translation on reported fourth-quarter sales was negligible.
Jun 02–Jun 05
The theme of this year’s annual meeting of The Canadian Association for Laboratory Animal Science (CALAS) is “The Heart of the Matter.” In addition, to an exhibit, Charles River is pleased to be participating in this year’s meeting with three posters, a technical presentation and a workshop.
Jun 05–Jun 08
This intensive seminar is designed to provide an overview on the basics of LAL test technology with in-depth analysis on the types of test methodology available. In particular, this seminar will focus on problems sometimes encountered in endotoxin testing, including resolving interference issues. The speakers will be available to answer any of your endotoxin testing-related questions.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
Charles River Laboratories, Inc.